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Effect of Peritoneal Dialysis Combined with Hemodialysis on End-stage
Renal Disease
Jing Wu, Yan Zha, Pinghong He
Guizhou Province People’s Hospital, Guiyang, China
Objective: To explore the curative effect of hemodialysis combined with
peritoneal dialysis treating the end-stage renal disease.
Methods: Selected 120 patients who were diagnosed end-stage renal disease
in our department from July 2012 to December 2013. According to the types
of dialysis, they were randomly and equally divided into combination group,
hemodialysis group and peritoneal dialysis group. Follow up for 3 years,
observed renal function, biochemical index, lipid metabolism, renal
morphology and blood flow signal changes, as well as the incidence of com-
plications and survival of three groups befor and after treatment.
Results: After different treatments, renal functions of three groups of patients
were significantly improved. The urea nitrogen (BUN) and serum creatinine
(Scr) of the combination group had no significant difference from hemodialysis
group (P> 0.05), but they were significantly lower than that of peritoneal dial-
ysis group (P < 0.05). The levels of hemoglobin and albumin of the combined
groupwere significantly higher than peritoneal dialysis and hemodialysis group,
and the differences were statistically significant (P< 0.05). Compared with he-
modialysis group, the rising amplitudes of hemoglobin and red blood cells of
peritoneal dialysis were higher (P < 0.05) but the level of albumin (ALB) was
lower (P < 0.05). Compared with peritoneal dialysis group, the combination
group had lower levels of triglyceride (TG), low density lipoprotein (LDL-C),
very low density lipoprotein (VLDL) and a higher level of high-density lipopro-
tein increased (HDL-C) (P < 0.05), but a less significantly different level of
the total cholesterol (TC) (P > 0.05).
Conclusion: Combined dialysis treatment for end-stage renal disease has
better effect, less complications and increased survival rate, and is worth
of clinical promotion.http://dx.doi.org/10.1016/j.hkjn.2015.09.231
0358
Analysis of Clinical Features of Peritoneal Dialysis-related Peritonitis
Shuang Chen, Yan Zha
Guizhou Province People’s Hospital, Guiyang, China
Objective: To understand the status of clinical features and pathogenic bac-
teria by analyzed the related factor, in order to improve the patients’ qual-
ity of life.
Methods: Selected the patients from January 2012 to December 2014, and
recorded each patient’s gender, age, primary disease, intestinal disorders
(diarrhea or constipation), peritoneal fluid culture, serum albumin, hemo-
globin, serum creatinine, serum calcium, serum phosphorus, parathyroid
hormone, peritoneal dialysis age. Summed up the pathogenic bacteria,
clarify the dangerous factors of PD related peritonitis.
Results: (1) There were 46 cases including 58 times of PD related peritonitis
in total of 126 cases, and 47 cases culture positive in the 58 times of perito-
neal fluid culture, the positive rate was 81.03%, including 29 cases with
Gram-positive cocci (61.70%), Gram-negative bacilli in 12 cases (25.53%), 6
cases of fungus (12.76%). (2) There was no difference between the two group
of patients’ age, gender, dialysis age and primary disease. (3) Peritonitis pa-
tients’ red blood cell, hemoglobin, serum albumin, serum calcium levels
were lower than the control group (P < 0.05). (4) Peritonitis group diar-
rhea/constipation increased significantly compared with the control group
(P < 0.01). (5) Peritonitis group of 58 patients with a total of three deaths,
6 cases changed to hemodialysis, the rest of the patients were cured. The 6
cases of fungal peritonitis, 4 cases had extubation and changed hemodialy-
sis, 2 cases died.
Conclusion: (1) Gram-positive bacteria are the most common pathogens in
PD-related peritonitis. (2) Poor nutrition, anemia, electrolyte disorder,bowel dysfunction are the risk factor of PD-related peritonitis. (3) Fungal
peritonitis had a higher rate of mortality and dropout rates.http://dx.doi.org/10.1016/j.hkjn.2015.09.2320361
Regular Urokinase Intervention in Catheter Maintenance in Patients
with Maintenance Haemodialysis
Ying Hu, Yan Zha, Shan He
Guizhou Province People’s Hospital, Guiyang, China
Objective: Explore the efficacy of Long-term catheter maintenance in ure-
mia patients with regular thrombolysis therapy by urokinase.
Methods: Forty uremia patients were recruited from our hospital between
October 2008 and December 2014. They were all received blood purification
average from 3 to 6 years. All of them were cuff tube. 21 patients were
male, average age, 68.40. They were divided into two groups randomly:
group A (19 cases), they were treated with thrombolysis therapy by uroki-
nase after dialysis. These patients received thrombolysis therapy by uroki-
nase regularly (once every 2 weeks), sealed with heparin when blood
purification were ended. And control group (21 cases) only treated with hep-
arin sealing. Then compare the index changes, such as Bun, Scr, KT/v, PT,
APTT.
Results: Compared blood flow, venous pressure, Bun, Scr, PT and APTT of the
two group patients before treatment. There were no statistically significant
differences (all P > 0.05). The levels of venous pressure of urokinase inter-
vention group on a regular basis was 68 30.5 mmHg, BUN (7.2 3.7 mmol/
l), Scr (200.5 90.4 umol/l), there were statistically significant difference
(all P < 0.05). CRP obviously reduced after the intervention compared
with control group; the blood flow and KT/v obviously increased, there
were statistically significant differences (all P < 0.05). There were no statis-
tically significant differences (all P > 0.05) of PT and APTT. There were 2
cases in the group thrombolysis therapy by urokinase, accounting for 11%.
Ten people in the control group, accounting for 47%. There were no statisti-
cally significant differences (P > 0.05) of bleeding.
Conclusion: Thrombolysis therapy by urokinase regularly can improve the
quality of dialysis patients, reduce the incidence of catheter thrombosis
and extending the service life of the catheter.http://dx.doi.org/10.1016/j.hkjn.2015.09.2330362
Effects of Serum of Hemodialysis Patients on TF and PAI-1 Secretion by
Human Vascular Endothelial Cells During Treatment with Atorvastatin
and Anticoagulant
Wen Zeng, Yan Zha, Ying Hu
Guizhou Province People’s Hospital, Guiyang, China
Objective: To elucidate the effects of serum of patients with hemodialysis
on tissue factor (TF) and plasminogen activator inhibitor-1 (PAl-1) secretion
of human vascular endothelial cells (HUVEC) during treat of atorvastatin and
anticoagulant.
Methods: Twenty patients who snuffbox arteriovenous fistula (SAV) or central
venous catheterization in hemodialysis patients involved were divided into
two groups randomly, 10 patients treated with atorvastatin and anticoagulant
and the others with anticoagulant for 3 months. The blood was collected from
patients at 0 months, 1 month, 2 months, and 3 months during treatment.
Serum TNF-a, IL-1bwere measured by ELlSA. TF and PAl-1 secretion of HUVEC
stimulated with serum of patients with hemodialysis undergoing drug treat-
ment were detected. TF and PAl-1 expression level were assayed by RT- PCR.
Results: TF and PAl-1 secretion were significantly increased in HUVEC stim-
ulated with serum of patients with haemodialysis, but the levels were
decreased after treatment with atorvastatin and anticoagulant. The secre-
tion of TNF-a and IL-1b that atorvastatin and anticoagulant group were lower
than atorvastatin group.
Conclusion: Serum of patients with hemodialysis promote the secretion of
TF and PAI-1 in HUVEC. The dysfunction of HUVEC induced by serum of pa-
tients with hemodialysis may be related to mediators of inflammation. Treat
